ELIXIR

Sosei Heptares Adds World-leading Expertise to its Scientific Advisory Board

Retrieved on: 
Wednesday, September 20, 2023
SAB, Medicinal chemistry, Chinese National Human Genome Center, Beijing, Nature Structural & Molecular Biology, University, Genomics, ELIXIR, United States Air Force Scientific Advisory Board, Astbury, GPCR, School, Clinical Therapeutics, Biophysics, Human musculoskeletal system, Growth, Pharmacology, Therapy, Pharmaceutical industry, Fine chemical, Medical device, Chemistry

Tokyo, Japan and Cambridge, UK, 20 September 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) announces the appointment of four new members to its Scientific Advisory Board (SAB) to advise on the Company’s scientific and early development strategy in support of its corporate objectives.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 20 September 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) announces the appointment of four new members to its Scientific Advisory Board (SAB) to advise on the Company’s scientific and early development strategy in support of its corporate objectives.
  • Sosei Heptares’ SAB includes world-leading experts from academia and the pharmaceutical industry in the US and Europe, each of whom is highly regarded in their respective fields.
  • Brief biographies are below and more information is available on the Sosei Heptares website .
  • Matt Barnes, President of Heptares Therapeutics and Head of UK R&D, said: “On behalf of myself and Malcolm Weir (Chair of the SAB), we are delighted to welcome these renowned experts to our truly exceptional Scientific Advisory Board.

DRIVING PRECISION MEDICINE FORWARD: BIO-IT WORLD EUROPE CONVENES IN LONDON 29-30 NOVEMBER 2023

Retrieved on: 
Thursday, September 21, 2023
Cloud, Partnership, Barts Health NHS Trust, LDN, Data management, Neoplasm, ELIXIR, Biotechnology, Cancer, Biomedical Research, Bioinformatics, Research, RDN, Queen Mary University of London, Government, Organization, Medicine, Drug discovery, Cloud computing, AI, MOSAIC, Conference, FAIR, Pharmaceutical industry

Senior-level scientists and researchers, IT professionals and executives from organizations across life sciences, including pharmaceutical, biotechnology, health systems, academia, government, and national laboratories, will participate in more than 60 sessions in five tracks--R&D in pharma, AI for Pharma, Storage Infrastructure & Cloud Computing, Data Management, and Bioinformatics.

Key Points: 
  • LONDON, Sept. 21, 2023 /PRNewswire/ -- To foster collaboration among the UK and Europe's biopharma and technology leaders who are forging new frontiers in precision medicine, the Bio-IT World Conference & Expo Europe is coming to London 29-30 November 2023.
  • Sessions will showcase the role of AI, FAIR (findable, accessible, interoperable and reusable) data, digital twins, bioinformatics and other technologies in catalyzing progress.
  • Examples include:
    A partnership between Barts Health NHS Trust and Queen Mary University of London, which are investing £600m pounds in a world-leading open-access exascale causal AI computing platform.
  • "Bio-IT World Europe will give participants an exclusive opportunity to network with the people behind the innovations originating in Europe and the UK.

BC Platforms, Euformatics and Oncompass Medicine form a partnership to develop oncology NGS workflows for buyer consortium of seven major European hospitals

Retrieved on: 
Wednesday, May 18, 2022
PCP, Software, NGS, SME, Medicine, Medical University of Graz, University of Florence, Pathology, Patient, Erasmus MC, Contract, Workflow, Association, H2020, EQA, Medical school, BC, Research, ELIXIR, DIGITALEUROPE, Partnership, Cancer Research Institute, Program, University, Hospital, Neoplasm, Union, BCP, Technology, Drug development, Precision medicine, Quality control, Intelligence, Ng Hui Ern, DNA sequencing, Cancer, University of Milano-Bicocca, Classification, IP, CEO, Pharmaceutical industry, Medical device, Medical imaging, EU, European, Central Europe

The buyer consortium, represented by the Medical University Graz, evaluated all proposals, and awarded a contract to the consortium of BC Platforms, Euformatics and Oncompass Medicine.

Key Points: 
  • The buyer consortium, represented by the Medical University Graz, evaluated all proposals, and awarded a contract to the consortium of BC Platforms, Euformatics and Oncompass Medicine.
  • The joint proposal by BC Platforms, Euformatics and Oncompass Medicine was evaluated by leading experts and selected for funding.
  • Oncompass was the first to develop a software as a medical device based on artificial intelligence that proved to improve therapeutic decisions in precision oncology.
  • Oncompass also provides end-to-end services for oncology centers that wish to provide precision oncology to their patients.

BC Platforms, Euformatics and Oncompass Medicine form a partnership to develop oncology NGS workflows for buyer consortium of seven major European hospitals

Retrieved on: 
Wednesday, May 18, 2022
PCP, Software, NGS, SME, Medicine, Medical University of Graz, University of Florence, Pathology, Patient, Erasmus MC, Contract, Workflow, Association, H2020, EQA, Medical school, BC, Research, ELIXIR, DIGITALEUROPE, Partnership, Cancer Research Institute, Program, University, Hospital, Neoplasm, Union, BCP, Technology, Drug development, Precision medicine, Quality control, Intelligence, Ng Hui Ern, DNA sequencing, Cancer, University of Milano-Bicocca, Classification, IP, CEO, Pharmaceutical industry, Medical device, Medical imaging, EU, European, Central Europe

The buyer consortium, represented by the Medical University Graz, evaluated all proposals, and awarded a contract to the consortium of BC Platforms, Euformatics and Oncompass Medicine.

Key Points: 
  • The buyer consortium, represented by the Medical University Graz, evaluated all proposals, and awarded a contract to the consortium of BC Platforms, Euformatics and Oncompass Medicine.
  • The joint proposal by BC Platforms, Euformatics and Oncompass Medicine was evaluated by leading experts and selected for funding.
  • Oncompass was the first to develop a software as a medical device based on artificial intelligence that proved to improve therapeutic decisions in precision oncology.
  • Oncompass also provides end-to-end services for oncology centers that wish to provide precision oncology to their patients.

LIX Announces Expansion of Product Line into Southwest Region

Retrieved on: 
Thursday, February 10, 2022
Marketing, BITE, ELIXIR, Collection, Rio Grande, PETS, Animal, Dog, LIX, Entrepreneurship, Partnership, Cannabinoid, Smell, Airline, Bottled water, CBD, Pacific Northwest

CANBY, Ore., Feb. 10, 2022 /PRNewswire/ -- LIX , the Oregon-based holistic pet wellness company, today formally announced a partnership with regional pet products distributor Rio Grande Service Center.

Key Points: 
  • CANBY, Ore., Feb. 10, 2022 /PRNewswire/ -- LIX , the Oregon-based holistic pet wellness company, today formally announced a partnership with regional pet products distributor Rio Grande Service Center.
  • This new partnership will continue the expansion of LIX's unique and diverse product line from the Pacific Northwest into the Southwest markets.
  • "After seeing the quick success LIX has had in the Pacific Northwest market, we're thrilled to bring a line of products like LIX to the Southwest region.
  • LIX products taste great across the board, are kind to furry or not-so furry friends, kind to our world, and kind to our bank accounts.

Leading IDO Incubator, Starter, Launches its First Play-to-Earn Blockchain Game “Starchi”

Retrieved on: 
Wednesday, November 3, 2021
BSC, FTM, ROI, Tamagotchi, ETH, Human, Starter, IDO, AVAX, ELIXIR, Blockchain, KYC, Iđoš, GLOBE, Decentralized finance, Cryptocurrency, Public relations

As our first play-to-earn game, Starchi grasps at the roots of the issues faced by our society today.

Key Points: 
  • As our first play-to-earn game, Starchi grasps at the roots of the issues faced by our society today.
  • Its exciting to see so many of our users interested in the concept and the purpose of the game.
  • Starchi will operate on a dual token economy with the $START token to be used as a way to grant access to the game and trade Starchi.
  • Starters community has provided hassle-free funding to many well known IDO launches and now adds Starchi to the list.

Play-to-earn Blockchain Game Starchi Wins Grant from Polygon Foundation

Retrieved on: 
Tuesday, September 14, 2021
Cardano, Fantom, KYC, PETS, IDO, Tamagotchi, Adoption, SDK, Collector, ELIXIR, Solution, Starter, GLOBE, Decentralized finance, Cryptocurrency, Toy

Starchi is a purposeful game characterized by adoptable digital pets called Starchis that need to be raised, fed and entertained in a virtual environment.

Key Points: 
  • Starchi is a purposeful game characterized by adoptable digital pets called Starchis that need to be raised, fed and entertained in a virtual environment.
  • Within the game, Starchi Collectors are tasked with acquiring and nurturing Starchis from infancy to adulthood.
  • Starchi operates as a dual token economy with Starters START token ($START) and Starchi Liquid Luck token ($ELIXIR).
  • Collectors can begin their Starchi journey here https://starchi.gg/ and for more details regarding Starters Starchi game, future Collectors may visit https://starter.xyz/ .

Lance Neill Joins Elixir as New Chief Operating Officer

Retrieved on: 
Tuesday, September 7, 2021
Health, Retail, Pharmaceutical, Managed Care, Convenience Store, Rite Aid Corporation, Elixir, RITE AID CORPORATION, ELIXIR

Elixir, a wholly owned subsidiary of Rite Aid (NYSE: RAD) that provides pharmacy benefits and services, today announced that veteran healthcare and pharmacy executive Lance Neill has joined the company as chief operating officer.

Key Points: 
  • Elixir, a wholly owned subsidiary of Rite Aid (NYSE: RAD) that provides pharmacy benefits and services, today announced that veteran healthcare and pharmacy executive Lance Neill has joined the company as chief operating officer.
  • At Elixir, he will oversee the core operational functions, including Elixir Insurance.
  • Lance is a seasoned and trusted industry executive who consistently delivers results, said Heyward Donigan, president and chief executive officer, Rite Aid.
  • In the months to come, I will work closely with Lance and the rest of the Elixir executive team to continue our march forward."